Substrates and potential therapeutics of ventricular arrhythmias in heart failure

Dongze Zhang, Huiyin Tu, Michael Charles Wadman, Yulong Li

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Heart failure (HF) is a clinical syndrome characterized by ventricular contractile dysfunction. About 50% of death in patients with HF are due to fetal ventricular arrhythmias including ventricular tachycardia and ventricular fibrillation. Understanding ventricular arrhythmic substrates and discovering effective antiarrhythmic interventions are extremely important for improving the prognosis of patients with HF and reducing its mortality. In this review, we discussed ventricular arrhythmic substrates and current clinical therapeutics for ventricular arrhythmias in HF. Base on the fact that classic antiarrhythmic drugs have the limited efficacy, side effects, and proarrhythmic potentials, we also updated some therapeutic strategies for the development of potential new antiarrhythmic interventions for patients with HF.

Original languageEnglish (US)
Pages (from-to)349-356
Number of pages8
JournalEuropean Journal of Pharmacology
Volume833
DOIs
StatePublished - Aug 15 2018

Fingerprint

Cardiac Arrhythmias
Heart Failure
Ventricular Dysfunction
Therapeutics
Anti-Arrhythmia Agents
Ventricular Fibrillation
Ventricular Tachycardia
Mortality

Keywords

  • Antiarrhythmic drugs
  • Catheter ablation
  • Heart failure
  • Ventricular arrhythmia
  • Ventricular arrhythmic substrate

ASJC Scopus subject areas

  • Pharmacology

Cite this

Substrates and potential therapeutics of ventricular arrhythmias in heart failure. / Zhang, Dongze; Tu, Huiyin; Wadman, Michael Charles; Li, Yulong.

In: European Journal of Pharmacology, Vol. 833, 15.08.2018, p. 349-356.

Research output: Contribution to journalArticle

@article{b207b5e520fa498486cb3bce8dd40ba3,
title = "Substrates and potential therapeutics of ventricular arrhythmias in heart failure",
abstract = "Heart failure (HF) is a clinical syndrome characterized by ventricular contractile dysfunction. About 50{\%} of death in patients with HF are due to fetal ventricular arrhythmias including ventricular tachycardia and ventricular fibrillation. Understanding ventricular arrhythmic substrates and discovering effective antiarrhythmic interventions are extremely important for improving the prognosis of patients with HF and reducing its mortality. In this review, we discussed ventricular arrhythmic substrates and current clinical therapeutics for ventricular arrhythmias in HF. Base on the fact that classic antiarrhythmic drugs have the limited efficacy, side effects, and proarrhythmic potentials, we also updated some therapeutic strategies for the development of potential new antiarrhythmic interventions for patients with HF.",
keywords = "Antiarrhythmic drugs, Catheter ablation, Heart failure, Ventricular arrhythmia, Ventricular arrhythmic substrate",
author = "Dongze Zhang and Huiyin Tu and Wadman, {Michael Charles} and Yulong Li",
year = "2018",
month = "8",
day = "15",
doi = "10.1016/j.ejphar.2018.06.024",
language = "English (US)",
volume = "833",
pages = "349--356",
journal = "European Journal of Pharmacology",
issn = "0014-2999",
publisher = "Elsevier",

}

TY - JOUR

T1 - Substrates and potential therapeutics of ventricular arrhythmias in heart failure

AU - Zhang, Dongze

AU - Tu, Huiyin

AU - Wadman, Michael Charles

AU - Li, Yulong

PY - 2018/8/15

Y1 - 2018/8/15

N2 - Heart failure (HF) is a clinical syndrome characterized by ventricular contractile dysfunction. About 50% of death in patients with HF are due to fetal ventricular arrhythmias including ventricular tachycardia and ventricular fibrillation. Understanding ventricular arrhythmic substrates and discovering effective antiarrhythmic interventions are extremely important for improving the prognosis of patients with HF and reducing its mortality. In this review, we discussed ventricular arrhythmic substrates and current clinical therapeutics for ventricular arrhythmias in HF. Base on the fact that classic antiarrhythmic drugs have the limited efficacy, side effects, and proarrhythmic potentials, we also updated some therapeutic strategies for the development of potential new antiarrhythmic interventions for patients with HF.

AB - Heart failure (HF) is a clinical syndrome characterized by ventricular contractile dysfunction. About 50% of death in patients with HF are due to fetal ventricular arrhythmias including ventricular tachycardia and ventricular fibrillation. Understanding ventricular arrhythmic substrates and discovering effective antiarrhythmic interventions are extremely important for improving the prognosis of patients with HF and reducing its mortality. In this review, we discussed ventricular arrhythmic substrates and current clinical therapeutics for ventricular arrhythmias in HF. Base on the fact that classic antiarrhythmic drugs have the limited efficacy, side effects, and proarrhythmic potentials, we also updated some therapeutic strategies for the development of potential new antiarrhythmic interventions for patients with HF.

KW - Antiarrhythmic drugs

KW - Catheter ablation

KW - Heart failure

KW - Ventricular arrhythmia

KW - Ventricular arrhythmic substrate

UR - http://www.scopus.com/inward/record.url?scp=85049304742&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85049304742&partnerID=8YFLogxK

U2 - 10.1016/j.ejphar.2018.06.024

DO - 10.1016/j.ejphar.2018.06.024

M3 - Article

VL - 833

SP - 349

EP - 356

JO - European Journal of Pharmacology

JF - European Journal of Pharmacology

SN - 0014-2999

ER -